Published in Blood Weekly, December 11th, 2003
These are malignant disorders of blood cell production that eventually lead to acute leukemia and affect approximately 300,000 people worldwide. Revimid has received fast track designation from the U.S. Food and Drug Administration (FDA) for the treatment of MDS and for multiple myeloma, a bone marrow cancer that results in more than 14,000 new cases each year.
"Preliminary results of the study show that Revimid may increase the growth of red blood cells (erythropoiesis) and demonstrate...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.